Amlodipine

Generic Name: Amlodipine

Brand Names: Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O_₅

CAS Number: 88150-42-9

Unique Ingredient Identifier: 1J444QC288

Background: Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...

Indication: Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)
...

Associated Conditions: Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-05-18

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 894

Registration Number: NCT00327145

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-03-17

Last Posted Date: 2016-11-16

Lead Sponsor: Novartis

Target Recruit Count: 1288

Registration Number: NCT00304226

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-02-09

Last Posted Date: 2007-03-06

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT00289406

Locations: 🇰🇷
SKChemicals, Seoul, Korea, Republic of

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine 5 mg
Drug: Telmisartan 20 mg
Drug: Amlodipine 2.5 mg
Drug: Telmisartan 40 mg
Drug: Placebo
Drug: Telmisartan 80 mg
Drug: Amlodipine 10 mg

First Posted Date: 2006-01-25

Last Posted Date: 2014-03-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1461

Registration Number: NCT00281580

Locations: 🇲🇽
1235.1.203, Col. Magdalena de las Salinas, Mexico
🇲🇽
1235.1.208 "Ignacio Chávez", mexico DF, Mexico
🇲🇽
1235.1.211 Obesidad Y Prevencion de Enfermedades, Mexico, D.F., Mexico

and more 133 locations

Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities

Phase 4

Completed

Conditions: Metabolic Syndrome X
Hypertension

First Posted Date: 2005-10-21

Last Posted Date: 2023-12-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT00242814

Locations: 🇫🇷
502.486.3302A Cabinet Médical, Angers, France
🇫🇷
502.486.3323A Cabinet Médical, Angers, France
🇫🇷
502.486.3307A Cabinet Médical, Chemille, France

and more 28 locations

Amlodipine as add-on to Olmesartan in Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

First Posted Date: 2005-09-22

Last Posted Date: 2018-12-24

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 429

Registration Number: NCT00220220

Olmesartan as an add-on to Amlodipine in Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

First Posted Date: 2005-09-22

Last Posted Date: 2018-12-24

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 632

Registration Number: NCT00220233

Rationale and Design for Shiga Microalbuminuria Reduction Trial

Phase 4

Conditions: Hypertension
Diabetes Mellitus
Albuminuria

First Posted Date: 2005-09-20

Last Posted Date: 2006-04-27

Lead Sponsor: Shiga University

Target Recruit Count: 160

Registration Number: NCT00202618

Locations: 🇯🇵
Shiga University of Medical Science, Otsu, Shiga, Japan

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-09-16

Last Posted Date: 2018-12-24

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1900

Registration Number: NCT00185133

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-09-16

Last Posted Date: 2012-01-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 152

Registration Number: NCT00185120

Locations: 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
Apex Research Institute, Santa Ana, California, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy